Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals (NASDAQ: TERN) could be a lucrative investment for those who missed out on Viking Therapeutics' (NASDAQ: VKTX) 300% surge, as TERN-601, its anti-obesity drug, shows promising phase 1 results and plans to advance to phase 2 in 2025. Terns' stock could mirror Viking's success, with potential for higher upside despite higher risk.
Reference News
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals (NASDAQ: TERN) could be a lucrative investment for those who missed out on Viking Therapeutics' (NASDAQ: VKTX) 300% surge, as TERN-601, its anti-obesity drug, shows promising phase 1 results and plans to advance to phase 2 in 2025. Terns' stock could mirror Viking's success, with potential for higher upside despite higher risk.